KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.

Joseph F Merola, Lyn Guenther, Charles Lynde, Kim A Papp, Lawrence Charles Parish, Paul Yamauchi, Sue Cheng, Hamid Amouzadeh, Cynthia Deignan, Shauna Jardon, Mindy Chen, Andreas Pinter

J Eur Acad Dermatol Venereol 40(2) 274-284

PMID41369155
PMCIDPMC12843872
DOI10.1111/jdv.70110
发表日期2025-12-10
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。
摘要

摘要

BACKGROUND: Genital psoriasis is highly prevalent among patients with psoriasis, is often stigmatized, causes pain and discomfort and negatively impacts quality of life. Apremilast is an oral phosphodiesterase 4 inhibitor approved for treating psoriasis and has demonstrated safety and efficacy in treating genital psoriasis, as seen in the primary 16-week DISCREET results. OBJECTIVES: To assess the efficacy and safety of apremilast 30 mg twice daily in patients with moderate to severe genital psoriasis over the 32-week study duration. METHODS: DISCREET was a phase 3, multicentre, randomized, double-blind trial that evaluated apremilast 30 mg twice daily versus placebo in a 16-week placebo-controlled phase (randomization 1:1) followed by a 16-week apremilast extension phase. Patients had moderate to severe genital psoriasis, defined as a modified static Physician's Global Assessment of Genitalia (genital PGA) score of ≥3. They also either had disease inadequately controlled by or were intolerant to topical therapy. We report the results through Week 32. RESULTS: Of 289 patients randomized, 229 continued to the apremilast extension phase (Weeks 16-32): 110 in the placebo/apremilast group and 119 in the apremilast/apremilast group. At 32 weeks, 51.8% (95% CI: 42.6, 60.9) of patients in the placebo/apremilast group and 40.3% (95% CI: 32.0, 49.3) of patients in the apremilast/apremilast group had achieved a modified genital PGA response (score of 0/1 with ≥2-point reduction from baseline). At Week 32, similar improvements in skin, genital signs and symptoms and quality of life were observed in patients who started apremilast at Week 16 or at randomization. Frequently reported treatment-emergent adverse events during all-apremilast exposure were diarrhoea (25.4%), nausea (19.4%) and headache (17.9%). CONCLUSIONS: Apremilast is an effective oral systemic therapy in patients with moderate to severe genital psoriasis and has shown consistent clinical efficacy, lessening of symptoms and quality-of-life benefit in DISCREET. CLINICAL TRIAL ID: NCT03777436.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 CONSORT diagram of the DISCREET trial. APR, apremilast 30 mg twice daily; PBO, placebo. a A total of 109 patients received ≥1 dose of apremilast.
非 KM Figure
FIGURE 2FIGURE 2 Physician‐reported outcomes over 32 weeks, including modified genital PGA responses (score of 0/1 with ≥2‐point reduction from baseline) (a), overall sPGA responses (score of 0/1 with ≥2‐point reduction from baseline) (b), and percent change from baseline in BSA (c). Data shown in panels (a, b) are based on patients who entered the apremilast extension phase with non‐responder imputation for missing data. Data shown in panel (c) are least‐squares means based on the mixed effects model for repeated measures during the PBO‐controlled period (Weeks 0–16) and based on data as observed during the apremilast extension phase (Weeks 16–32). Error bars represent 95% CI. APR, apremilast 30 mg twice daily; BSA, body surface area; CI, confidence interval; genital PGA, static Physician's Global Assessment of Genitalia; PBO, placebo; sPGA, static Physician's Global Assessment.
非 KM Figure
FIGURE 3FIGURE 3 Patient‐reported outcomes over 32 weeks, including GPI‐NRS responses (a), change from baseline in GPSS total score (b), change from baseline in DLQI (c) and change from baseline in DLQI‐Q9 (d). Data shown in panel (a) are based on patients who entered the apremilast extension phase with non‐responder imputation for missing data. Panel (a) includes patients with a baseline GPI‐NRS score of ≥4. Data shown in panels (b–d) are least‐squares means based on the mixed effects model for repeated measures during the PBO‐controlled phase (Weeks 0–16) and based on data as observed during the apremilast extension phase (Weeks 16–32). Error bars represent 95% CI. APR, apremilast 30 mg twice daily; CI, confidence interval; DLQI, Dermatology Life Quality Index; DLQI‐Q9, Dermatology Life Quality Index Question 9; GPI‐NRS, Genital Psoriasis Itch Numeric Rating Scale; GPSS, Genital Psoriasis Symptoms Scale; PBO, placebo.
非 KM Figure